- Cell Biology
- Product Type
- Research Area
- New Products
- About Tocris
- Contact Us
M3 receptors are members of the G-protein-coupled receptor (GPCR) family which are found mostly bound to Gq proteins. They are one of five muscarinic receptors that act to control the metabotropic functions of acetylcholine (ACh) in the central nervous system (CNS).
|Cat No||Product Name / Activity|
|Muscarinic M3 antagonist|
|2096||DAU 5884 hydrochloride|
|M3 receptor antagonist|
|2507||J 104129 fumarate|
|Potent and selective M3 antagonist|
M3 receptors are members of the G-protein-coupled receptor (GPCR) family which are found mostly bound to Gq proteins. They are one of five muscarinic receptors that act to control the metabotropic functions of acetylcholine (ACh) in the central nervous system (CNS). M3 receptors are most densely populated in smooth muscle, endocrine and exocrine glands, lungs and CNS.
Activation of the M3 receptor leads to several responses, including the upregulation of phospholipase C, and inositol triphosphate (IP3), therefore increasing intracellular Ca2+. Hence, M3 receptor agonism can lead to smooth muscle constriction and bronchoconstriction. Conversely, receptor activation on vascular endothelial cells may upregulate the vasodilator nitric oxide (NO). Activation of M3 receptors also contributes towards many secretions (for example from the salivary gland, pancreas or stomach). Overall, M3 receptors are involved in numerous metabolic functions, including the maintenance of insulin release, regulation of glucose homeostasis.
M3 receptor antagonism is a potential therapeutic target in the treatment pulmonary obstructions. Activation of the M3 receptor by selective agonists may also be beneficial in the treatment of Type 2 diabetes.
Tocris offers the following scientific literature for M3 Receptors to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.